Clinical Trial Update: FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating FOLFOXIRI plus panitumumab in Kras and BRAF wild-type metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Panitumumab (panitumumab)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Metastatic Colo-rectal Cancer | Phase 2 | Status: COMPLETED